Background
Stockholders brought this derivative action on behalf of The Beauty Health Company after problems emerged with its HydraFacial Syndeo skincare device. The complaint alleged that directors and officers failed to oversee hardware, software, and design defects, while the company characterized the problems as “teething issues” in public communications. In November 2023, Beauty Health declared first- and second-generation Syndeo devices obsolete and offered replacements, incurring more than $63 million in write-downs and remediation expenses.
After Section 220 investigations, the plaintiffs asserted fiduciary-duty claims framed as Caremark oversight claims and a corporate-waste claim attacking a $100 million stock-repurchase program. The parties settled while defendants’ Rule 23.1 demand-futility motion was pending. The settlement supplied governance measures including formal charters for existing management committees, a designated quality ombudsperson, quarterly inventory and return reports to the board, an Audit Committee charter amendment, and an expanded clawback policy.
The Court’s Holding
Vice Chancellor Will approved the settlement as fair, reasonable, and adequate. The court held that the released claims were exceptionally weak: the complaint itself alleged that the board received information about Syndeo’s defects and remediation, undermining a Caremark theory. The alleged concealment of product problems did not amount to the affirmative lawbreaking-for-profit theory associated with Massey, and the challenge to open-market share repurchases did not state waste.
The court found the settlement consideration similarly modest. Most reforms formalized existing practices, created operational rather than structural changes, or lacked a logical connection to the alleged harm. But because the release gave up claims with little prospect of success, the minor therapeutic benefits were adequate consideration. The court awarded $100,000 inclusive of expenses to counsel for the litigating plaintiffs, reduced from the requested $737,500; awarded nothing to counsel for a stockholder who made a later demand; and denied requested service awards.
Key Takeaways
- A derivative settlement may be approved when modest reforms are commensurate with the weakness of the claims released.
- Allegations that a board received reports on product defects and remediation do not support a Caremark claim merely because the response was allegedly inadequate.
- Fees for minor therapeutic benefits should reflect the actual corporate benefit, not counsel’s reported hours or an uncontested request.
Why It Matters
The decision emphasizes the court’s independent role in reviewing both derivative settlements and fee applications. Parties cannot justify a substantial fee by assigning speculative dollar values to incremental governance measures or by invoking broad studies about corporate-governance premiums.
It also cautions against late-filed stockholder demands during active derivative litigation. Tactical settlement leverage, without an independent corporate benefit, does not justify sharing in a fee award.